Kidney Cancer Coverage from Every Angle

Leonard J. Appleman, MD, PhD, on Pazopanib After Metastasectomy in Renal Cell Carcinoma

Posted: Monday, June 24, 2019

Leonard J. Appleman, MD, PhD, of the UPMC Hillman Cancer Center, discusses, in light of phase III results from the ECOG-ACRIN E2810 trial, the potential role for pazopanib treatment in patients with advanced kidney cancer who have no evidence of disease after metastasectomy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.